Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready
Academisch Ziekenhuis Maastricht maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. These matters are distributed across 7 distinct examiners and 5 distinct art units. This distribution suggests a broad prosecution strategy across multiple specialized groups within the USPTO. Because the pending office actions are spread across the distinct examiners, no single examiner holds a majority of the workload.
The busiest examiner for the portfolio is PAK, YONG D, who is responsible for 1 pending office action. Practitioners should prepare for varied examination styles across the 5 distinct art units currently engaged. The presence of distinct examiners for the 7 pending office actions indicates that every current matter is being handled by a different individual. This requires a case-specific approach to prosecution rather than a unified strategy tailored to a single examiner's habits or preferences. The 5 distinct art units involved further suggest that the technical scope of the portfolio is diverse within the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, YONG D | 1 | 74.6% | +14.3% |
| BOSQUES, EDELMIRA | 1 | 63.0% | +20.6% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| PEEBLES, KATHERINE | 1 | 35.5% | +48.6% |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
| YU, HONG | 1 | 30.9% | +5.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 189d overdue |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 22d overdue |
| 18880021 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | PAK, YONG D | — |
| 18722298 | Immunoprotective Type Implantable Cell Delivery Device | BOSQUES, EDELMIRA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 189d overdue |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 22d overdue |
| 18029391 | 3D STRUCTURES FOR CELL GROWTH | MARTIN, PAUL C | 8d overdue |
| 18880021 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | PAK, YONG D | — |
| 18722298 | Immunoprotective Type Implantable Cell Delivery Device | BOSQUES, EDELMIRA | — |
| 18576049 | MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1653 | 1 |
| 1617 | 1 |
| 1622 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18880021 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | PAK, YONG D | 1652 | §102§103§112 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18722298 | Immunoprotective Type Implantable Cell Delivery Device | BOSQUES, EDELMIRA | — | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18576049 | MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES | BORGEEST, CHRISTINA M | — | §112 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18029391 | 3D STRUCTURES FOR CELL GROWTH | MARTIN, PAUL C | 1653 | §103 | Non-Final OA | 8d overdue | Pending | Mar 30, 2023 |
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 1617 | §102§103§112 | Non-Final OA | 189d overdue | Pending | Aug 04, 2022 |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 1622 | §103§112 | Final Rejection | 22d overdue | Pending | Aug 04, 2022 |
| 17292028 | BIOINKS | YU, HONG | 1614 | §103 | Non-Final OA | — | Pending | May 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial